Principal Investigator

Sylvain Meloche

Signalling and Cell Growth

Subscribe to the newsletter

After obtaining his PhD in molecular pharmacology from the Université de Montréal in 1988, Sylvain Meloche completed a postdoctoral fellowship in immunology at the Montreal Clinical Research Institute, followed by a second fellowship in biochemistry at the Université de Nice in France.

In 1992, he began his teaching career and established his research activities at the Centre hospitalier de l’Université de Montréal. He is a founding member of IRIC and principal investigator of the Cell Signaling and Growth Research Unit. Sylvain Meloche is also a full professor in the Department of Pharmacology and Physiology at the Faculty of Medicine of the Université de Montréal.

Principal Investigator, Signalling and Cell Growth Research Unit
High-Throughput Screening Core Facility Scientific direction

Professor, Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal

Research unit on signalling and cell growth

Marcelle-Coutu Pavilion, 2306-5

Phone (office)
(514) 343-6966
Fax
(514) 343-7780
Email
sylvain.meloche@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Signalling and Cell Growth

Sylvain Meloche and his team study the signalling mechanisms that control cell division, the differentiation and survival of normal and cancer cells. The research aims to identify novel therapeutic targets for cancer treatment based on these mechanisms.

Discover the research unit View the research team

Research topics

Publications

  • November 1, 2025

    CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability.

    Boucher J, Houles T, Berliocchi E, Lavoie G, MacLeod G, Saba-El-Leil MK, Angers S, Meloche S, Roux PP
    Cell Rep 2025-11-01 ;44( 11 ):116495

  • October 22, 2025

    Intracellular pH regulates ubiquitin-mediated degradation of the MAP kinase ERK3.

    Tesnière C, Boudghene-Stambouli F, Severin M, Poët M, Voisin L, Ponniah M, Pascariu M, Bonneil E, Trempe JF, Thibault P, Counillon L, Pedersen SF, Meloche S
    Proc Natl Acad Sci U S A 2025-10-22 ;122( 43 ):e2501825122

  • August 27, 2025

    ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity.

    Morazzo S, Fernandes S, Fortea M, Skálová H, Pereira-Sousa D, Cassani M, Vrzalová K, Kafka F, Vrbský J, Soulez M, Meloche S, Morten-Seternes O, Bosáková V, Shin J, Frič J, Haase K, Forte G
    Front Oncol 2025-08-27 ;15:1563969

  • April 3, 2025

    Brain-wide mapping of immune receptors uncovers a neuromodulatory role of IL-17E and the receptor IL-17RB.

    Lee Y, Ishikawa T, Lee H, Lee B, Ryu C, Davila Mejia I, Kim M, Lu G, Hong Y, Feng M, Shin H, Meloche S, Locksley RM, Koltsova E, Grivennikov SI, Heiman M, Choi GB, Huh JR
    Cell 2025-04-03 ;

  • See all publications

News

  • October 31, 2023

    A CRS grant to validate therapeutic targets in liver cancer

    The team led by Sylvain Meloche, Director of IRIC’s Signaling and Cell Growth Research Unit, has been awarded a two-year grant of $125,000 for the project “Advanced preclinical validation of SRC-family kinases as therapeutic targets in liver cancer”. This grant is funded in partnership with the Canadian Liver Foundation.

  • See all news

Awards and distinctions

  • Project Grant - Canadian Institutes of Health Research, 2021

  • Canada Research Chair (tier 1) in Cellular Signaling, 2011-2018

  • Canada Research Chair (tier 1) in Cellular Signaling, 2004-2011

  • Biotechnology of Tomorrow Award, Genesis Awards, 2009

  • National Investigator, The Fonds de recherche du Québec – Santé, 2003-2004

  • Scientist, Medical Research Council of Canada, 1998-2003

  • Joe Doupe Young Investigator Award, Canadian Society for Clinical Investigation, 1995

  • Scholar, Medical Research Council of Canada, 1992-1997

    • See all awards